Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial
Semaglutide improved walking function in people with PAD and type 2 diabetes, including individuals without obesity and those with well-controlled HbA1c. Benefits were consistent across BMI and HbA1c categories, supporting effectiveness beyond weight or glycemic changes.
Authors
- Andrei‐Mircea Catarig (ORCID: https://orcid.org/0000-0002-7667-8315)
- Joakim Nordanstig (ORCID: https://orcid.org/0000-0002-2670-2268)
- Harald Sourij (ORCID: https://orcid.org/0000-0003-3510-9594)
- Kim Christian Houlind (ORCID: https://orcid.org/0000-0002-1600-4415)
- Bernhard Ludvik (ORCID: https://orcid.org/0000-0001-9843-9385)
- Subodh Verma (ORCID: https://orcid.org/0000-0002-4018-8533)
- Neda Rasouli (ORCID: https://orcid.org/0000-0003-1269-3580)
- Marc P. Bonaca (ORCID: https://orcid.org/0000-0002-9860-3584)
- Ecenur Guder Arslan
- Sebastian Thomas
Institutions
- St. Michael's Hospital (CA)
- University of Southern Denmark (DK)
- University of Toronto (CA)
- Novo Nordisk (Denmark) (DK)
- Medical University of Graz (AT)
- Lillebaelt Hospital (DK)
- VA Eastern Colorado Health Care System (US)
- Novo Nordisk (India) (IN)
- Karl Landsteiner Society (AT)
- University of Gothenburg (SE)
- University of Colorado Denver (US)
Publication Details
- Journal
- Diabetes Care
- Published
- 2025-06-21
- DOI
- https://doi.org/10.2337/dc25-1082
- Citations
- 6
- Primary Topic
- Peripheral Artery Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 12.04
Funders
- Pfizer
- Sanofi
- Yale University
- Medpace
- Osiris Therapeutics
- Regeneron Pharmaceuticals
- Prothena
- Kowa Company
- Novo Nordisk
- Silence Therapeutics
- Feinstein Institutes for Medical Research